The iCannToolkit: a tool to embrace measurement of medicinal and non-medicinal cannabis use across licit, illicit and cross-cultural settings

Valentina Lorenzetti, Chandni Hindocha, Kat Petrilli, Paul Griffiths, Jamie Brown, Álvaro Castillo-Carniglia, Jonathan P. Caulkins, Amir Englund, Mahmoud A. ElSohly, Suzanne H. Gage, Teodora Groshkova, Antoni Gual, David Hammond, Will Lawn, Hugo López-Pelayo, Jakob Manthey, Claire Mokrysz, Rosalie Liccardo Pacula, Margriet van Laar, Ryan VandreyElle Wadsworth, Adam Winstock, Wayne Hall, H. Valerie Curran, Tom P. Freeman

Research output: Contribution to journalComment/debatepeer-review

1 Citation (SciVal)
Original languageEnglish
Pages (from-to)1523-1525
Number of pages3
JournalAddiction
Volume117
Issue number6
Early online date15 Mar 2022
DOIs
Publication statusPublished - Jun 2022

Bibliographical note

Funding Information:
This study was supported by the Society for the Study of Addiction, European Monitoring Centre for Drugs and Drug Addiction. H.L.P. works under the CERCA Programme/Generalitat de Catalunya and receives funding from the Spanish Ministry of Science, Innovation and Universities, Instituto de Salud Carlos III through a ‘Juan Rodes’ contract (JR19/00025). V.L. was supported by a Val & Al Rosenstrauss Senior Research Fellowship and by an Australian Catholic University competitive Scheme. A.C.C. received funding from ANID—Millennium Science Initiative Program, no. NCS2021_003 and no. NCS2021_013.

Funding Information:
A.G. received funding from Novartis for work outside this area (a phase III cocaine trial). A.E. has received speaker a honorarium from GW Pharmaceuticals. A.W. is the founder of the Global Drug Survey. C.H. became a full‐time employee of GW Pharmaceuticals after the consensus meeting. D.H. has served as a paid expert witness on behalf of public health authorities in Canada in response to legal challenges from the cannabis industry. H.L. has received honoraria and travel grants from Janssen and Lundbeck. J.B. has received unrestricted research funding to study smoking cessation from companies who manufacture smoking cessation medications (Pfizer and J&J). R.V. receives consulting fees for Canopy Health Innovations and Syqe Medical Ltd, and is on the Scientific Advisory Board for MyMD Pharmaceuticals and Artiam Bio Inc. V.C. has consulted for Janssen. V.L., W.H., T.P.F., E.W., T.G., W.L., A.C.C., J.P.C., R.L.P., M.v.L., K.P., P.G., M.A.E., S.H.G., J M. and C M. have no competing interests to declare.

Funding Information:
This study was supported by the Society for the Study of Addiction, European Monitoring Centre for Drugs and Drug Addiction. H.L.P. works under the CERCA Programme/Generalitat de Catalunya and receives funding from the Spanish Ministry of Science, Innovation and Universities, Instituto de Salud Carlos III through a ?Juan Rodes? contract (JR19/00025). V.L. was supported by a Val & Al Rosenstrauss Senior Research Fellowship and by an Australian Catholic University competitive Scheme. A.C.C. received funding from ANID?Millennium Science Initiative Program, no. NCS2021_003 and no. NCS2021_013.

Keywords

  • Assessment
  • cannabis
  • dose
  • iCannToolkit
  • international cannabis toolkit
  • measurement
  • standardization

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Psychiatry and Mental health

Cite this